TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32703216
Drug: AA mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA mixture containing 1.8 g of arginine, 1.1 g of valine, and 0.1 g of serine
Study: 32271637
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin alone at a dose of 0.3 mg/kg/day
Study: 32271637
Drug: Candida antigen
Normalized name: Candida antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida antigen alone at a dose of 0.1 ml of 1/1000 solution into the largest wart
Study: 32271637
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Candida antigen and oral isotretinoin by the same method and dose
Study: 33187759
Drug: Interim methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim methadone treatment plus patient navigation (IM + PN)
Study: 33187759
Drug: Interim methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim methadone treatment (IM)
Study: 32359668
Drug: Enhanced Treatment-as-Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment-as-Usual (ETAU)
Study: 35679902
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (HA, PRP, HA+PRP)
Study: 34409891
Drug: HAD-B1 (972
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAD-B1 (972 mg)
Study: 34409891
Drug: HAD-B1 (1944
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAD-B1 (1944 mg)
Study: 32246262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers including carnosine
Study: 35679775
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment
Study: 36162887
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) with diode laser (980 nm, 100 mW for 1 minute)
Study: 33986125
Drug: Ipilimumab administered
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered immediately after sipuleucel-T
Study: 33986125
Drug: Ipilimumab administered
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered delayed 3 weeks after sipuleucel-T
Study: 33986125
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of sipuleucel-T and ipilimumab
Study: 33986125
Drug: Prior localized
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior localized radiation therapy (RT)
Study: 34969423
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention using behavioural counselling with nicotine replacement therapy (NRT) gum
Study: 34444773
Drug: Heavy cream
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy cream (HC)
Study: 32030887
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily until disease progression
Study: 35089218
Drug: Febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40 mg daily before contrast agent and hydration
Study: 33685500
Drug: Salvianolate 200
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvianolate 200 mg intravenously dripped for 30 min and then for 7 days
Study: 33685500
Drug: Salvianolate 200
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvianolate 200 mg
Study: 33120356
Drug: 10‐minute ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐minute ice massage prior to iontophoresis treatment
Study: 34304234
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 30 mg/kg with IV placebo
Study: 34304234
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 15 mg/kg with oral placebo
Study: 32690730
Drug: Not using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not using drugs
Study: 33837482
Drug: Pai‐Neng‐Da Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pai‐Neng‐Da Capsule (PNDC) 320 mg/d plus cyclosporine 5 mg/(kg·d) plus andriol 80 mg/d
Study: 34438327
Drug: Riboflavin deficiency
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin deficiency diet (1.48 mg riboflavin/kg)
Study: 34438327
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (16.48 mg riboflavin/kg)
Study: 32958820
Drug: Elective nodal
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Study: 32958820
Drug: Elective nodal
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Study: 32958820
Drug: Conventional field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Study: 32958820
Drug: Conventional field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Study: 33338463
Drug: Standard ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ultrasound-guided subacromial injections (40 mg triamcinolone acetonide)
Study: 33338463
Drug: Dual-target injections
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-target injections (20 mg triamcinolone acetonide for LHBT and supraspinatus tendons)
Study: 33589279
Drug: Extended oral
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended oral antibiotic prophylaxis for 7 days after discharge
Study: 33589279
Drug: No extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: No extended oral antibiotic prophylaxis
Study: 35416182
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g fish oil daily for 6 weeks
Study: 35416182
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g soybean oil daily for 6 weeks
Study: 35011059
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of each (fish oil and soybean oil) daily for 6 weeks
Study: 33720388
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg sugammadex
Study: 33894423
Drug: Placebo intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray
Study: 36413792
Drug: Low-dose Ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ara-C plus pegylated recombinant arginase BCT-100
Study: 33582621
Drug: Action observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action observation therapy in addition to exercise (n = 18)
Study: 32398113
Drug: Propranolol (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-80 mg twice daily) in addition to standard care
Study: 32398113
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care alone (i.e. anti-epileptic drugs or headache treatments)
Study: 36075235
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered after childbirth
Study: 36075235
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered after childbirth
Study: 33648495
Drug: Delay in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay in seeking treatment for pelvic organ prolapse
Study: 33648495
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with delay in treatment
Study: 32811613
Drug: Transcranial pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial pulsed ultrasound combined with alteplase intravenous thrombolysis
Study: 32811613
Drug: Alteplase intravenous
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase intravenous thrombolytic treatment
Study: 33032585
Drug: Curcumin 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 5% ointment
Study: 33032585
Drug: Vaseline ointment
Normalized name: petrolatum Topical Ointment [Vaseline]
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline ointment (placebo)
Study: 35096422
Drug: Suprachoroidal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA)
Study: 35096422
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA)
Study: 34438110
Drug: Lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine + Dexamethasone (3 cc 2% lidocaine + 1 cc dexamethasone, 4 mg)
Study: 34438110
Drug: Lidocaine alone
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine alone (3 cc 2% lidocaine + 1 cc normal saline)
Study: 32500131
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine (5 mg/kg)
Study: 32009778
Drug: Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dose Combination (FDC) of gemigliptin (50 mg) and rosuvastatin (20 mg)
Study: 32009778
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of gemigliptin (50 mg) and rosuvastatin (20 mg)
Study: 34948486
Drug: Early occupational
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early occupational therapy intervention program
Study: 33498049
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (150,000 IU daily for 3 days before surgery)
Study: 32800386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 μg) and vitamin-B12 (500 μg) supplementation
Study: 36121303
Drug: DPE technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPE technique with ropivacaine 0.1% and sufentanil 0.5 μg/mL
Study: 35159318
Drug: Selenium yeast
Normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day), n = 118
Study: 32570237
Drug: Low-dose OIT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OIT (20 mL; n = 19)
Study: 32570237
Drug: High-dose OIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose OIT (100 mL; n = 14)
Study: 33103925
Drug: 20-session schema
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-session schema group therapy plus treatment as usual (TAU) (n = 28)
Study: 33103925
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) alone (n = 14)
Study: 36046952
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral melatonin liquid
Study: 36046952
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral melatonin liquid
Study: 33657114
Drug: Early convalescent
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early convalescent plasma (CP) therapy
Study: 33657114
Drug: Deferred convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred convalescent plasma (CP) therapy
Study: 33811684
Drug: Music Video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Video (MV) therapy
Study: 34951444
Drug: CHD-PAL intervention
Normalized name: PEG-PAL
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CHD-PAL intervention (eight 30-min videoconferencing sessions over 20 weeks with an interventionist + Fitbit + exercise prescription)
Study: 34951444
Drug: Comparator (Fitbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (Fitbit + exercise prescription)
Study: 35351445
Drug: Norgestrel 0.075
Normalized name: norgestrel 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 0.075 mg progestogen-only pill
Study: 33758132
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL nalbuphine with 10 mL 0.1% ropivacaine
Study: 33758132
Drug: 0.3 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg/mL sufentanil with 10 mL 0.1% ropivacaine
Study: 32552387
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/tablet) + anti-TB therapy
Study: 32552387
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + anti-TB therapy
Study: 32940699
Drug: COBRA-light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light treatment arm
Study: 32940699
Drug: COBRA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA treatment arm
Study: 32974656
Drug: Internet-delivered Acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Acceptance and Commitment Therapy (ACT) for adolescents
Study: 32974656
Drug: Internet-delivered Acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Acceptance and Commitment Therapy (ACT) for parents
Study: 32807267
Drug: Healive vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healive vaccine
Study: 32807267
Drug: Havrix vaccine
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix vaccine
Study: 33796993
Drug: Furosemide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.05 to 0.4 mg/kg/h)
Study: 33301221
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) 13.8 g (two doses)
Study: 33301221
Drug: Bisacodyl 10
Normalized name: bisacodyl 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl 10 mg
Study: 33765513
Drug: lapatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: lapatinib + trastuzumab (L+T)
Study: 33765513
Drug: trastuzumab followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab followed by lapatinib (T→L)
Study: 35285241
Drug: Sutezolid 300
Normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid 300 mg
Study: 35285241
Drug: Sutezolid 600
Normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid 600 mg
Study: 35285241
Drug: Sutezolid 1200
Normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid 1200 mg
Study: 35285241
Drug: Sutezolid 1800
Normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid 1800 mg
Study: 35285241
Drug: Sutezolid (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid (all doses)
Study: 34006328
Drug: Daily tablet
Normalized name: One-Daily Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tablet PrEP
Study: 34006328
Drug: PrEP injection
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP injection or implant
Study: 34006328
Drug: On-base locations
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-base locations for lab evaluation and medication pick-up
Study: 32129892
Drug: Immunosuppressant (IS)
Normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppressant (IS) dose reduction
Study: 35177108
Drug: OPIOID (hydrocodone/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPIOID (hydrocodone/acetaminophen 5/300 mg)
Study: 35177108
Drug: NON‐OPIOID (ibuprofen/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NON‐OPIOID (ibuprofen/acetaminophen 400/500 mg)
Study: 32223762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving traditional oral health information
Study: 33508778
Drug: Regular ball
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular ball warm-up (156 g)
Study: 33508778
Drug: Heavier ball
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavier ball warm-up (171.6 g)
Study: 33508778
Drug: Lighter ball
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lighter ball warm-up (140.4 g)
Study: 35440501
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg/day
Study: 35576290
Drug: Short duration
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short duration steroid therapy
Study: 35576290
Drug: Long duration
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long duration steroid therapy
Study: 33347019
Drug: Nanocurcumin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin (160 mg/d)
Study: 32791940
Drug: Prior antiplatelet
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior antiplatelet therapy
Study: 32791940
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior antiplatelet therapy
Study: 32692952
Drug: ACLC patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLC patch
Study: 32692952
Drug: ACLC patch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLC patch, oblique brace, anterior brace
Study: 36257847
Drug: Colostomy closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostomy closure without mechanical bowel preparation (MBP)
Study: 36257847
Drug: Colostomy closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostomy closure with mechanical bowel preparation (MBP)
Study: 35681510
Drug: Systemic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparin
Study: 35033226
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) alone
Study: 35033226
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with low-dose radiotherapy (0.5 Gy delivered twice per day for 2 days during each of the first four cycles)
Study: 35033226
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with hypofractionated radiotherapy (24 Gy total delivered over three 8-Gy fractions during the first cycle only)
Study: 33272839
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy (four-week sessions over one month)
Study: 34865686
Drug: Binary dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Binary dance rhythm (12 weeks, twice a week, 45 minutes)
Study: 34865686
Drug: Quaternary dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quaternary dance rhythm (12 weeks, twice a week, 45 minutes)
Study: 34800427
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg once per day until discharge)
Study: 36999805
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia
Study: 34460181
Drug: Adding SGLT2
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding SGLT2 inhibitors
Study: 34460181
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to GLP-1 receptor agonists (GLP-1 RAs)
Study: 32057125
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate treatment
Study: 36204125
Drug: Low-dose NW
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NW Low-Glu® (4 capsules per day)
Study: 36204125
Drug: High-dose NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NW Low-Glu® (5 capsules per day)
Study: 36204125
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg per day)
Study: 33337815
Drug: EtaBS (Enerceptan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtaBS (Enerceptan) 50 mg weekly for 32 weeks
Study: 33337815
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg weekly for 32 weeks